FGF receptor mutations: Dimerization syndromes, cell growth suppression, and animal models

IUBMB Life

Volumn 49, Issue 3, 2000, Pages 197-205

  Kannan, Karuppiah ^a   Givol, David ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Chondrocytes; FGFR activation; Gene targeting; Mouse models; Skeletal dysplasia; Ternary complex

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR;

DIMERIZATION; DISEASE SEVERITY; ENZYME ACTIVATION; GENE MUTATION; NONHUMAN; REVIEW; SKELETON MALFORMATION; STRUCTURE ACTIVITY RELATION;

EID: 0034119439     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/152165400306205     Document Type: Review

References (65)

1. Burgess, W. H., and Maciag, T. (1989) The heparin binding (fibroblast) growth factor family of proteins. Annu. Rev. Biochem. 58, 575-606.
2. Coulier, F., Pontraotti, P., Roubin, R., Hartung, H., Goldfarb, M., and Birnbaum, D. (1997) Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J. Mol. Evol. 44, 43-56.
3. Ruta, M., Howk, R., Ricca, G., Drohan, W., Labelshansky, M., Laureys, G., Barton, E., Francke, U., Schlessinger, J., and Givol, D. (1988) A novel protein-tyrosine kinase gene whose expression is modulated during endothelial cell differentiation. Oncogene 3, 9-15.
4. Kornbluth, S., Paulson, K. E., and Hanafusa, H. (1988) Novel tyrosine kinase identified by phosphotyrosine antibody screening of cDNA libraries. Mol. Cell. Biol. 8, 5541-5544.
5. Lee, P. L., Johnson, D. E., Cousens, L. S., Fried, V. A., and Williams, L. T. (1989) Purification and cDNA cloning of a receptor for basic fibroblast growth factor. Science 245, 57-60.
6. Givol, D., and Yayon, A. (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J. 6, 3362-3369.
7. Jaye, M., Schlessinger, J., and Dionne, C. A. (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta. 1135, 185-199.
8. Johnson, D. E., and Williams, L. T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60, 1-41.
9. Basilico, C., and Moscatelli, D. (1992) The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59, 115-165.
10. 2-terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J. Biol. Chem. 270, 10231-10235.
11. Johnson, D. E., Lu, J., Chen, H., Wener, S., and Williams, L. T. (1991) The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol. Cell. Biol. 11, 4627-4634.
12. Miki, T., Bottaro, D. P., Fleming, T. P., Smith, C. L., Burgess, W. H., Chan, A. M., and Aaronson, S. A. (1992) Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc. Natl. Acad. Sci. U.S.A. 89, 246-250.
13. Yayon, A., Zimmer, Y., Hong, S. G., Avivi, A., Yarden, Y., and Givol, D. (1992) A confined variable region confers ligand specificity to fibroblast growth factor receptor. EMBO J. 11, 1885-1890.
14. Avivi, A., Yayon, A., and Givol, D. (1993) A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 330, 249-252.
15. Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., and Goldfarb, M. (1996) Receptor specificity of the fibroblast growth factor family. J. Biol. Chem. 271, 15292-15297.
16. Peters, K. G., Wener, S., Chen, G., and Williams, L. T. (1992) Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 114, 233-243.
17. Orr-Urtreger, A., Bedford, M. T., Burakova, T., Arman, E., Zimmer, Y., Yayon, A., Givol, D., and Lonai, P. (1993) Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev. Biol. 158, 475-486.
18. Murgue, B., Tsunekawa, S., Rosenberg, I., deBeaumont, M., and Podolsky, D. K. (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res. 54, 5206-5211.
19. Xu, X., Weinstein, M., Li, C., and Deng, C. X. (1999) Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Cell Tissue Res. 296, 33-43.
20. Naski, M. C., and Ornitz, D. M. (1998) FGF signaling in skeletal development. Front. Biosci. 3, D781-D794.
21. Arman, E., Haffner-Krausz, R., Gorivodsky, M., and Lonai, P. (1999) Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc. Natl. Acad. Sci. U.S.A. 96, 11895-11899.
22. Klagsbrun, M. (1990) The affinity of fibroblast growth factors for heparin; FGF-heparan sulfate interactions in cells and extracellular matrix. Curr. Biol. 2, 857-863.
23. Repraeger, A. C., Krufka, A., and Olwin, B. B. (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252, 1705-1708.
24. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12, 240-247.
25. Lemmon, M. A., and Schlessinger, J. (1994) Regulation of signal transduction and signal diversity by receptor oligomerisation. Trends Biochem. Sci. 19, 459-463.
26. Spivak-Kroizman, T., Lemmon, M. A., Dikic, I., Ladbury, J. E., Pinchasi, D., Huang, J., Jaye, M., Crumley, G., Schlessinger, J., and Lax, I. (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation and cell proliferation. Cell 79, 1015-1024.
27. DiGabrielle, A. D., Lax, I., Chen, D. I., Svahn, C. M., Jaye, M., Schlessinger, J., and Hendrickson, W. A. (1998) Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393, 812-817.
28. Pye, D. A., and Gallagher, J. T. (1999) Monomer complexes of basic fibroblast growth factor and heparan sulfate oligosaccharides are the minimal functional unit for cell activation. J. Biol. Chem. 274, 13456-13461.
29. Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J., and KcKeehan, W. L. (1993) An essential heparin binding domain in the fibroblast growth factor receptor kinase. Science 259, 1918-1921.
30. LaRochelle, W. J., Sakaguchi, K., Atabey, N., Cheon, H. G., Takagi, Y., Kinaia, T., Day, R. M., Miki, T., Burgess, W. H., and Bottaro, D. P. (1999) Heparan sulfate proteoglycan modulates keratinocyte growth factor signaling through interaction with both ligand and receptor. Biochemistry 38, 1765-1771.
31. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. (1999) Structural basis for FGF receptor dimerization and activation. Cell 98, 641-650.
32. Faham, S., Hileman, R. E., Fromm, J. R., Linhardt, R. J., and Rees, D. C. (1996) Heparin structure and interations with basic fibroblast growth factor. Science 271, 1116-1120.
33. Gray, T. E., Eisenstein, M., Shimon, T., Givol, D., and Yayon, A. (1995) Molecular modeling based mutagenesis defines ligand binding and specificity determining regions of fibroblast growth factor receptors. Biochemistry 34, 10325-10333.
34. Gray, T. E., Eisenstein, M., Yayon, A., and Givol, D. (1996) Asparagine-344 is a key residue for ligand binding in keratinocyte growth factor receptor. Biochemistry 35, 15640-15645.
35. Rousseau, F., Bonaventure, J., Ghouzzi, E. I., Legeai-Mallet, L., Pelet, A., Rozet, J. M., Delezoide, A. L., Maroteaux, P., Le Merrer, M., and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor 3 in achondroplasia. Nature 371, 252-254.
36. Shiang, R., Thompson, L. M., Zhu, Y.-Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T., and Wasmuth, J. J. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 787, 335-342.
37. Passo-Bueno, M. R., Wilcox, W. R., Jabs, E. W., Sertie, A. L., Alonso, L. G., and Kitoh, K. (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum. Mutat. 14, 115-125.
38. Cornejo-Roldan, L. R., Roessler, E., and Muenke, M. (1999) Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome. Hum. Genet. 104, 425-431.
39. Wilkie, A. O. M. (1997) Craniosynostosis: genes and mechanisms. Hum. Mol. Genet. 6, 1647-1656.
40. Webster, M. K., and Donoghue, D. J. (1997) FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 13, 178-182.
41. Bellus, G. A., Gaudenz, K., Zackai, E. H., Clark, L. A., Szabo, J., Francomano, C. A., and Muenke, M. (1996) Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat. Genet. 14, 174-176.
42. Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A., Delezoide, A. L., Maroteaux, P., Bonaventure, J., Nancy, F., and Sanak, M. (1995) Stop codon FGFR3 mutations in thanatophoric dwarfism type I. Nat. Genet. 10, 11-12.
43. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657.
44. Webster, M. K., and Donoghue, D. J. (1996) Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J. 15, 520-527.
45. Tavormina, P. L., Shiang, R., Tompson, L. M., Zhu, Y. Z., Wilkin, D. J., Lachman, R. S., Wilcox, W. R., Rimoin, D. L. Cohn, D. H., and Wasmuth, J. J. (1995) Thanatophoric dysplasia (types I and II) caused by direct mutations in fibroblast growth factor receptor 3. Nat. Genet. 9, 321-328.
46. Tavormina, P. L., Bellus, G. A., Webster, M., Bamshad, M. J., Fraley, A. R., McIntosh, I., Szabo, J., Jiang, W., Jabs, E. W., Wilcox, W. R., Wasmuth, J. J., Donoghue, D. J., Thompson, L. M., and Francomano, C. A. (1999) A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys-650-Met mutation in fibroblast growth factor receptor 3 gene. Am. J. Hum. Genet. 64, 722-731.
47. Wilcox, W. R., Tavormina, P. L., Krakow, D., Lachman, Wasmuth, J. J., Thompson, L. M., and Rimoin, D. L. (1998) Molecular, radiologic and histopathologic correlations in thanatophoric dysplasia. Am. J. Med. Genet. 78, 274-281.
48. Li, Y., Mangasarian, K. M., Mansukhani, A., and Basilico, C. (1997) Activation of FGF receptors by mutations in the transmembrane domain. Oncogene 14, 1397-1406.
49. Naski, M. C., Wang, Q., Xu, J., and Ornitz, D. M. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 13, 233-237.
50. Galvin, B. D., Hart, K. C., Meyer, A. N., Webster, M. K., and Donoghue, D. J. (1996) Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. Proc. Natl. Acad. Sci. U.S.A. 93, 7894-7899.
51. Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., and Greene, M. I. (1989) A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339, 230-231.
52. Anderson, J., Burns, H. D., Enriquez-Harris, P., Wilkie, A. O. M., and Heath, J. K. (1998) Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. Hum. Mol. Genet. 7, 1475-1483.
53. Webster, M. K., D'Avis, P. Y., Robertson, S. C., and Donoghue, D. J. (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol. Cell. Biol. 16, 4081-4087.
54. Cappellen, D., Oliveira, C. D., Ricol, D., Medina, S. G. D., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., and Radvanyi, F. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20.
55. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921.
56. Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G., and Ornitz, D. M. (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat. Genet. 12, 390-397.
57. Mancilla, E. E., De Luca, F., Uyeda, J. A., Czerwiec, F. S., and Baron, J. (1998) Effects of fibroblast growth factor-2 on longitudinal bone growth. Endocrinology 139, 2900-2904.
58. Coffin, J. D., Florkiewicz, R. Z., Neumann, J., Mort-Hopkins, T., Dorn, G. W., Lightfoot, P., German, R., Howles, P. N., Kier, A., O'Toole, B. A., Sasse, J., Gonzalez, A. M., Baird, A., and Doetschman, T. (1995) Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell. 6, 1861-1873.
59. Sahni, M., Ambrosetti, D. C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13, 1361-1366.
60. Su, W.-C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W. A., and Fu, X.-Y. (1997) Activation of Stal 1 by mutant fibroblast growth factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288-292.
61. Darnell, J. E. Jr. (1997) STATs and gene regulation. Science 277, 1630-1635.
62. WAFI/Cipl mediated by STAT1. Science 272, 719-722.
63. Naski, M. C., Colvin, J. S., Coffin, J. D., and Ornitz, D. M. (1998) Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977-4988.
64. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X.-Y., and Deng, C. X. (1999) A Lys644Glu substitution in fibroblat growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and INK4 cell cycle inhibitors. Hum. Mol. Genet. 8, 35-44.
65. Wang, Y., Spatz, M. K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, A., Lonai, P., and Givol, D. (1999) A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acas. Sci. U.S.A. 96, 4455-4460.